Zymeworks Inc. (NASDAQ: ZYME) appointed Kristin Stafford as its new Chief Financial Officer, effective April 1 2026. Stafford, 44, brings more than a decade of life‑sciences finance experience, having held senior roles at Royalty Pharma and BioPharma Credit. Her background in strategic planning, disciplined capital allocation, and complex capital‑market transactions is seen as a fit for Zymeworks’ evolving strategy.
Continue reading for full analysis...
Zymeworks Inc. announced that the U.S. Food and Drug Administration granted Fast‑Track designation to its antibody‑drug conjugate ZW191, an FRα‑targeting ADC intended for patients with advanced or metastatic platinum‑resistant ovarian cancer. The designation, granted on March 30 2026, is a regulatory milestone that may accelerate the drug’s development and review timeline.
Continue reading for full analysis...